Synlogic (SYBX) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	SYBX
Entity Registrant Name	SYNLOGIC, INC.
Security Exchange Name	NASDAQ
Entity Central Index Key	0001527599
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Entity Common Stock, Shares Outstanding		70,229,592
Entity Address, State or Province	MA
Entity File Number	001-37566
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1824804
Entity Address, Address Line One	301 Binney St.
Entity Address, Address Line Two	Suite 402
Entity Address, City or Town	Cambridge
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	401-9975
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 30,901	$ 16,438
Short-term marketable securities	75,890	112,150
Prepaid expenses and other current assets	4,306	4,721
Total current assets	111,097	133,309
Long-term marketable securities		8,041
Property and equipment, net	8,464	9,088
Right of use asset - operating lease	15,034	13,889
Restricted cash	1,097	1,097
Prepaid research and development, net of current portion	7,836	9,309
Other assets	17	3
Total assets	143,545	174,736
Current liabilities:
Accounts payable	1,502	1,944
Accrued expenses	3,249	4,402
Deferred revenue	149	531
Lease liability - operating lease	3,993	3,191
Finance lease obligations	13	12
Total current liabilities	8,906	10,080
Long-term liabilities:
Lease liability - operating lease, net of current portion	17,278	17,372
Finance lease obligations, net of current portion	11	18
Total long-term liabilities	17,289	17,390
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $0.001 par value 250,000,000 shares authorized as of June 30, 2022 and December 31, 2021. 70,230,235 shares issued and outstanding as of June 30, 2022 and 69,698,844 shares issued and outstanding as of December 31, 2021.	70	70
Additional paid-in capital	440,124	438,113
Accumulated other comprehensive loss	(433)	(45)
Accumulated deficit	(322,411)	(290,872)
Total stockholders' equity	117,350	147,266
Total liabilities and stockholders' equity	$ 143,545	$ 174,736

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	250,000,000	250,000,000
Common stock, Issued	70,230,235	69,698,844
Common stock, outstanding	70,230,235	69,698,844

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue	$ 152	$ 246	$ 396	$ 246
Operating expenses:
Research and development	12,057	10,719	23,795	21,899
General and administrative	4,112	4,061	8,383	7,912
Total operating expenses	16,169	14,780	32,178	29,811
Loss from operations	(16,017)	(14,534)	(31,782)	(29,565)
Other income (expense):
Interest and investment income	169	50	236	110
Interest expense	(1)	(1)	(2)	(1)
Other income	7		9
Other income (expense), net	175	49	243	109
Net loss	$ (15,842)	$ (14,485)	$ (31,539)	$ (29,456)
Net loss per share - basic	$ (0.22)	$ (0.28)	$ (0.44)	$ (0.63)
Net loss per share - diluted	$ (0.22)	$ (0.28)	$ (0.44)	$ (0.63)
Weighted-average common stock outstanding - basic	72,106,224	52,049,424	72,038,460	46,876,216
Weighted-average common stock outstanding - diluted	72,106,224	52,049,424	72,038,460	46,876,216
Comprehensive loss:
Net loss	$ (15,842)	$ (14,485)	$ (31,539)	$ (29,456)
Net unrealized (loss) gain on marketable securities	(88)	6	(388)	(3)
Comprehensive loss	$ (15,930)	$ (14,479)	$ (31,927)	$ (29,459)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	At-the-market Offering	Common Stock $0.001 Par Value	Common Stock $0.001 Par Value At-the-market Offering	Additional Paid-in Capital	Additional Paid-in Capital At-the-market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2020	$ 115,135		$ 38		$ 345,394		$ 14	$ (230,311)
Balance (in Shares) at Dec. 31, 2020			38,183,273
Balance at Mar. 31, 2021	109,050		$ 41		354,286		5	(245,282)
Balance (in Shares) at Mar. 31, 2021			40,873,526
Balance at Dec. 31, 2020	115,135		$ 38		345,394		14	(230,311)
Balance (in Shares) at Dec. 31, 2020			38,183,273
Exercise of options	64				64
Exercise of options, shares			32,113
Issuance of common stock under employee stock purchase plan	33				33
Issuance of common stock under employee stock purchase plan, Shares			19,061
Proceeds from issuance of common stock, net of issuance costs	32,575	$ 8,050	$ 11	$ 3	32,564	$ 8,047
Proceeds from issuance of common stock, net of issuance costs, Shares			11,500,000	2,447,211
Issuance of restricted stock, shares			242,454
Restricted stock awards withheld for payment of employees' withholding tax liability	(73)				(73)
Restricted stock awards withheld for payment of employees' withholding tax liability, Shares			18,187
Cancellation of restricted stock			30,581
Equity-based compensation expense	1,753				1,753
Unrealized gain (loss) on securities	(3)						(3)
Net loss	(29,456)							(29,456)
Balance at Jun. 30, 2021	128,078		$ 52		387,782		11	(259,767)
Balance (in Shares) at Jun. 30, 2021			52,375,344
Balance at Mar. 31, 2021	109,050		$ 41		354,286		5	(245,282)
Balance (in Shares) at Mar. 31, 2021			40,873,526
Exercise of options	64				64
Exercise of options, shares			31,897
Proceeds from issuance of common stock, net of issuance costs	32,575		$ 11		32,564
Proceeds from issuance of common stock, net of issuance costs, Shares			11,500,000
Restricted stock awards withheld for payment of employees' withholding tax liability	(8)				(8)
Restricted stock awards withheld for payment of employees' withholding tax liability, Shares			2,217
Cancellation of restricted stock			27,862
Equity-based compensation expense	876				876
Unrealized gain (loss) on securities	6						6
Net loss	(14,485)							(14,485)
Balance at Jun. 30, 2021	128,078		$ 52		387,782		11	(259,767)
Balance (in Shares) at Jun. 30, 2021			52,375,344
Balance at Dec. 31, 2021	147,266		$ 70		438,113		(45)	(290,872)
Balance (in Shares) at Dec. 31, 2021			69,698,844
Exercise of options	61				61
Exercise of options, shares			35,562
Issuance of common stock under employee stock purchase plan	83				83
Issuance of common stock under employee stock purchase plan, Shares			40,490
Issuance of restricted stock, shares			507,260
Cancellation of restricted stock			51,921
Equity-based compensation expense	1,867				1,867
Unrealized gain (loss) on securities	(388)						(388)
Net loss	(31,539)							(31,539)
Balance at Jun. 30, 2022	117,350		$ 70		440,124		(433)	(322,411)
Balance (in Shares) at Jun. 30, 2022			70,230,235
Balance at Mar. 31, 2022	132,294		$ 70		439,138		(345)	(306,569)
Balance (in Shares) at Mar. 31, 2022			70,267,586
Exercise of options	9				9
Exercise of options, shares			4,940
Issuance of common stock under employee stock purchase plan, Shares			(38)
Cancellation of restricted stock			42,253
Equity-based compensation expense	977				977
Unrealized gain (loss) on securities	(88)						(88)
Net loss	(15,842)							(15,842)
Balance at Jun. 30, 2022	$ 117,350		$ 70		$ 440,124		$ (433)	$ (322,411)
Balance (in Shares) at Jun. 30, 2022			70,230,235

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (31,539)	$ (29,456)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,257	1,232
Equity-based compensation expense	1,867	1,753
Accretion/amortization of investment securities	(87)	184
Change in carrying amount of operating lease right of use asset	1,554	979
Changes in operating assets and liabilities:
Accounts receivable		(1,000)
Prepaid expenses and other current assets	415	183
Prepaid research and development, net of current portion	1,473	1,426
Accounts payable and accrued expenses	(1,599)	(260)
Deferred revenue	(382)	904
Operating lease liabilities	(1,991)	(1,264)
Other assets	(14)	(2)
Net cash used in operating activities	(29,046)	(25,321)
Cash flows from investing activities:
Purchases of marketable securities	(41,116)	(74,010)
Proceeds from maturity of marketable securities	85,116	54,272
Proceeds from redemption of marketable securities		1,270
Purchases of property and equipment	(629)	(123)
Net cash provided by (used in) investing activities	43,371	(18,591)
Cash flows from financing activities:
Payments on finance lease obligations	(6)	(3)
Proceeds from issuance of common stock, net of issuance costs		32,578
Proceeds from employee stock purchases and exercise of stock options	144	97
Payment of employee withholding taxes relating to restricted stock awards		(73)
Net cash provided by financing activities	138	40,649
Net increase (decrease) in cash, cash equivalents and restricted cash	14,463	(3,263)
Cash, cash equivalents and restricted cash at beginning of period	17,535	33,604
Cash, cash equivalents and restricted cash at end of period	31,998	30,341
Supplemental disclosure of non-cash investing activities:
Assets acquired under operating lease obligation	2,699	460
Property and equipment purchases included in accounts payable and accrued expenses	4	225
Supplemental disclosure of non-cash financing activities:
Purchase under finance lease		36
Issuance costs included in accounts payable and accrued expenses		3
Cash paid for interest	$ 1	1
At-the-market Offering
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		$ 8,050

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	(1) Nature of Business Organization Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or “the Company”), is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Biotics are generated from Synlogic’s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drug candidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop and ultimately commercialize Synthetic Biotics. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates. Risks and Uncertainties At June 30, 2022, the Company had approximately $ 106.8 million in cash, cash equivalents, and short-term marketable securities, $ 1.1 million of restricted cash and an accumulated deficit of approximately $ 322.4 million. Since its inception through June 30, 2022, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, collaborations, including with Roche, and cash received in the Merger (defined below). In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements. As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances. COVID-19 While the Company is not aware of a material impact from the continuation of the COVID-19 pandemic through June 30, 2022 , the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations, and financial condition, including expenses and manufacturing, clinical trials, and research and development costs, depends on future developments that are uncertain at this time.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies The significant accounting policies described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (SEC) on March 17, 2022 (the 2021 Annual Report), have had no material changes during the three and six months ended June 30, 2022. Basis of Presentation The accompanying consolidated financial statements and the related disclosures as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2021 and 2020 audited consolidated financial statements and notes included in the 2021 Annual Report. The consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Recently Issued Accounting Pronouncements New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(3) Fair Value of Financial Instruments The tables below present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2 , Summary of Significant Accounting Policies, in the audited financial statements included in the 2021 Annual Report. The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data. At June 30, 2022 and December 31, 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at Reporting Date Using June 30, Quoted Prices in Active Significant Other Significant Description 2022 (Level 1) (Level 2) (Level 3) Money market funds $ 21,912 $ 21,912 $ — $ — Commercial paper (included in cash and cash equivalents) 8,989 — 8,989 $ — Commercial paper 56,614 — 56,614 — Corporate debt securities — — — — U.S. government agency securities and treasuries 19,276 19,276 — — Total $ 106,791 $ 41,188 $ 65,603 $ — Fair Value Measurements at Reporting Date Using December 31, Quoted Prices in Active Significant Other Significant Description 2021 (Level 1) (Level 2) (Level 3) Money market funds $ 16,437 $ 16,437 $ — $ — Commercial paper 106,277 — 106,277 — Corporate debt securities 5,873 — 5,873 — U.S. government agency securities and treasuries 8,041 8,041 — — Total $ 136,628 $ 24,478 $ 112,150 $ — Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at June 30, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at June 30, 2022 and December 31, 2021 approximate fair value as they bear interest at a rate approximating a market interest rate.

Available-for-Sale Investments

Available-for-Sale Investments	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Available-for-Sale Investments	(4) Available-for-Sale Investments The following tables summarize the available-for-sale securities held at June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 Amortized cost Gross unrealized Gross unrealized Fair Value Commercial paper $ 56,852 $ — $ ( 238 ) $ 56,614 Corporate debt securities — — — — U.S. government agency securities and treasuries 19,471 — ( 195 ) 19,276 Total $ 76,323 $ — $ ( 433 ) $ 75,890 December 31, 2021 Amortized cost Gross unrealized Gross unrealized Fair Value Commercial paper $ 106,298 $ 8 $ ( 29 ) $ 106,277 Corporate debt securities 5,876 — ( 3 ) 5,873 U.S. government agency securities and treasuries 8,062 — ( 21 ) 8,041 Total $ 120,236 $ 8 $ ( 53 ) $ 120,191 The contractual maturity of all securities held at June 30, 2022 was 11 months or less. There were 27 and 20 investments in an unrealized loss position at June 30, 2022 and December 31, 2021, respectively, none of which had been in an unrealized loss position for more than twelve months. The aggregate fair value of the securities in an unrealized loss position at June 30, 2022 and December 31, 2021 was $ 75.9 million and $ 72.2 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did no t hold any securities with an other-than-temporary impairment at June 30, 2022. Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	(5) Property and Equipment, net Property and equipment, net consists of the following (in thousands): June 30, December 31, 2022 2021 Laboratory equipment $ 9,196 $ 8,274 Computer and office equipment 795 756 Furniture and fixtures 500 500 Leasehold improvements 9,820 9,561 Construction in progress 37 623 20,348 19,714 Less accumulated depreciation ( 11,884 ) ( 10,626 ) Property and equipment, net $ 8,464 $ 9,088

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	(6) Accrued Expenses Accrued expenses consist of the following (in thousands): June 30, December 31, 2022 2021 Payroll related $ 2,203 $ 3,495 Professional fees 632 298 Research and development 216 336 Other 198 273 Total accrued expenses $ 3,249 $ 4,402

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	(7) Stockholders’ Equity In June 2019, the Company issued to Ginkgo Bioworks, Inc. (Ginkgo) an aggregate of 6,340,771 shares of common stock at a purchase price per share of $ 9.00 , and pre-funded warrants (the Pre-Funded Warrants) to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $ 9.00 per share, with $ 8.99 of such exercise price paid at the closing of the offering. The net proceeds to the Company were approximately $ 79.9 million. No ne of the Pre-Funded Warrants have been exercised as of June 30, 2022. (See Note 9, Collaboration Agreements : Ginkgo Collaboration ). The Company had a previous sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market (ATM) offering program, which was entered into on October 13, 2017. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the three months ended March 31, 2021, 2,447,211 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $ 8.1 million. There were no sales pursuant to the Cowen ATM subsequent to March 31, 2021. In July 2021, the Company entered into a new sales agreement with Jefferies, LLC (Jefferies) with respect to an ATM, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having aggregate sales proceeds of up to $ 50.0 million. Jefferies is not required to sell any specific amount but acts as the Company’s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. During the six months ended June 30, 2022, no shares of common stock were sold pursuant to the sales agreement with Jefferies. The Company has reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan: June 30, 2022 Common stock issuable under pre-funded warrants 2,548,117 Options exercisable to purchase common stock 2,707,904 Employee Stock Purchase Plan 20,705 Total 5,276,726

Equity-based Compensation

Equity-based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity-based Compensation	(8) Equity‑based Compensation On January 1, 2022, the number of shares of common stock available for issuance under the 2015 Equity Incentive Award Plan (the “2015 Plan”) and the 2015 Employee Stock Purchase Plan (“ESPP”) was increased by 3,484,942 shares and 696,988 shares, respectively, due to the annual evergreen provision to increase shares available under the 2015 Plan and the ESPP. As of June 30, 2022, there were an aggregate of 2,259,432 shares available for future grant under the 2017 Stock Incentive Plan (the 2017 Plan) and the 2015 Plan, and 1,341,339 shares available for future grant under the ESPP. The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 378 $ 359 $ 753 $ 774 General and administrative 599 517 1,114 979 $ 977 $ 876 $ 1,867 $ 1,753 The following table summarizes equity‑based compensation expense by type of award for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30 Six Months Ended June 30, 2022 2021 2022 2021 Stock options $ 845 $ 800 $ 1,665 $ 1,499 Restricted stock awards 113 62 166 234 ESPP 19 14 36 20 $ 977 $ 876 $ 1,867 $ 1,753 During the six months ended June 30, 2022, the Company granted 2,889,149 stock options with a weighted average exercise price of $ 1.84 . As of June 30, 2022, there was $ 6.6 million of unrecognized share-based compensation related to unvested stock option grants which is expected to be recognized over a weighted average period of 2.8 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur. During the six months ended June 30, 2022, the Company granted 507,260 restricted stock awards with a weighted average grant date fair value per share of $ 1.97 . As of June 30, 2022, there was approximately $ 1.4 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 3.3 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur. For a full description of the Company’s equity plans, refer to Note 9, Equity-based Compensation and Equity Incentive Plans in the 2021 Annual Report.

Collaboration Agreements

Collaboration Agreements	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Agreements	(9) Collaboration Agreements Roche Collaboration In June 2021, the Company entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, the Company and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease. During the six months ended June 30, 2022, the Company recognized $ 0.4 million as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss associated with the Roche Collaboration and Option Agreement. Deferred revenue from the collaboration amounted to $ 0.1 million as of June 30, 2022, all of which is included in current liabilities. For a full description of the Roche Collaboration and Option Agreement, refer to Note 10, Collaboration Agreements in the 2021 Annual Report. Ginkgo Collaboration In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products (See Note 7). Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $ 30.0 million for its foundry services that will be provided to the Company over an initial term of five years . The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the June 30, 2022 consolidated balance sheet. At June 30, 2022, the Company had remaining balances of $ 1.7 million and $ 7.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	(10) Net Loss per Share Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock and outstanding stock options. In June 2019, the Company sold 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $ 9.00 per share, with $ 8.99 of such exercise price paid at the closing of the offering (see Note 10 , Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report). The shares of common stock into which the warrants may be exercised are considered outstanding for the purposes of computing net loss per share. The Company’s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect. As of June 30, 2022 2021 Unvested restricted common stock awards 670,950 346,461 Outstanding options to purchase common stock 6,923,868 4,605,714 Potential shares issuable under the ESPP 20,705 10,240

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11) Commitments and Contingencies In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings. The Company’s commitments are described in the Company’s consolidated financial statements as of and for the year ended December 31, 2021 and the notes thereto included in the Annual Report on Form 10-K filed with the SEC on March 17, 2022. On January 21, 2022, the Company entered into two Statements of Work with Azzur Group, LLC (Azzur). Pursuant to the first of the SOWs (the Third SOW), the Company has agreed to pay Azzur $ 650,000 to renovate and upgrade the cleanroom space at Azzur for the Company’s expanded use. The second of the SOWs (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur on April 29, 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). The Fourth SOW contains an option to extend the lease. As of June 30, 2022, the Company determined that it was more likely than not to exercise the option to extend the lease. The Third and Fourth SOWs resulted in an adjustment to the operating lease right-of-use asset and corresponding operating lease liabilities of $ 1.8 million. The total remaining liability associated with the Azzur lease is approximately $ 2.9 million as of June 30, 2022. For a full description of the Azzur embedded lease, refer to Note 13, Leases in the 2021 Annual Report.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	(12) Related-Party Transactions In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of June 30, 2022 , Ginkgo owned 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration, in the audited financial statements included in the 2021 Annual Report. Under the agreement the Company made a prepayment to Ginkgo of $ 30.0 million for its foundry services that will be provided to the Company over an initial term of five years . At June 30, 2022 , the Company had remaining balances of $ 1.7 million and $ 7.8 million of current and non-current pre-paid research and development costs related to this transaction, respectively. The Company used $ 1.2 million and $ 1.7 million of the pre-paid research and development expenses for the three and six months ended June 30, 2022 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements and the related disclosures as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2021 and 2020 audited consolidated financial statements and notes included in the 2021 Annual Report. The consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any other interim period or future year or period.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis	At June 30, 2022 and December 31, 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at Reporting Date Using June 30, Quoted Prices in Active Significant Other Significant Description 2022 (Level 1) (Level 2) (Level 3) Money market funds $ 21,912 $ 21,912 $ — $ — Commercial paper (included in cash and cash equivalents) 8,989 — 8,989 $ — Commercial paper 56,614 — 56,614 — Corporate debt securities — — — — U.S. government agency securities and treasuries 19,276 19,276 — — Total $ 106,791 $ 41,188 $ 65,603 $ — Fair Value Measurements at Reporting Date Using December 31, Quoted Prices in Active Significant Other Significant Description 2021 (Level 1) (Level 2) (Level 3) Money market funds $ 16,437 $ 16,437 $ — $ — Commercial paper 106,277 — 106,277 — Corporate debt securities 5,873 — 5,873 — U.S. government agency securities and treasuries 8,041 8,041 — — Total $ 136,628 $ 24,478 $ 112,150 $ —

Available-for-Sale Investments

Available-for-Sale Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Available-for-Sale Securities Held	The following tables summarize the available-for-sale securities held at June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 Amortized cost Gross unrealized Gross unrealized Fair Value Commercial paper $ 56,852 $ — $ ( 238 ) $ 56,614 Corporate debt securities — — — — U.S. government agency securities and treasuries 19,471 — ( 195 ) 19,276 Total $ 76,323 $ — $ ( 433 ) $ 75,890 December 31, 2021 Amortized cost Gross unrealized Gross unrealized Fair Value Commercial paper $ 106,298 $ 8 $ ( 29 ) $ 106,277 Corporate debt securities 5,876 — ( 3 ) 5,873 U.S. government agency securities and treasuries 8,062 — ( 21 ) 8,041 Total $ 120,236 $ 8 $ ( 53 ) $ 120,191

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following (in thousands): June 30, December 31, 2022 2021 Laboratory equipment $ 9,196 $ 8,274 Computer and office equipment 795 756 Furniture and fixtures 500 500 Leasehold improvements 9,820 9,561 Construction in progress 37 623 20,348 19,714 Less accumulated depreciation ( 11,884 ) ( 10,626 ) Property and equipment, net $ 8,464 $ 9,088

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): June 30, December 31, 2022 2021 Payroll related $ 2,203 $ 3,495 Professional fees 632 298 Research and development 216 336 Other 198 273 Total accrued expenses $ 3,249 $ 4,402

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Shares of Common Stock Reserved for Future Issuance	The Company has reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan: June 30, 2022 Common stock issuable under pre-funded warrants 2,548,117 Options exercisable to purchase common stock 2,707,904 Employee Stock Purchase Plan 20,705 Total 5,276,726

Equity-based Compensation (Tabl

Equity-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Equity-based Compensation Expenses	The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 378 $ 359 $ 753 $ 774 General and administrative 599 517 1,114 979 $ 977 $ 876 $ 1,867 $ 1,753
Schedule of Equity-based Compensation Expenses by Award Type	The following table summarizes equity‑based compensation expense by type of award for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30 Six Months Ended June 30, 2022 2021 2022 2021 Stock options $ 845 $ 800 $ 1,665 $ 1,499 Restricted stock awards 113 62 166 234 ESPP 19 14 36 20 $ 977 $ 876 $ 1,867 $ 1,753

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect. As of June 30, 2022 2021 Unvested restricted common stock awards 670,950 346,461 Outstanding options to purchase common stock 6,923,868 4,605,714 Potential shares issuable under the ESPP 20,705 10,240

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents, and short-term marketable securities	$ 106,800
Restricted cash	1,097	$ 1,097
Accumulated deficit	$ 322,411	$ 290,872

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	$ 106,791	$ 136,628
Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	21,912	16,437
Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	56,614	106,277
U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	19,276	8,041
Cash and Cash Equivalents
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	8,989
Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		5,873
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	41,188	24,478
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	21,912	16,437
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	19,276	8,041
Significant Other Observable Inputs (Level 2)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	65,603	112,150
Significant Other Observable Inputs (Level 2) | Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	56,614	106,277
Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	8,989
Significant Other Observable Inputs (Level 2) | Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		5,873
Significant Unobservable Inputs (Level 3)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Significant Unobservable Inputs (Level 3) | Commercial Paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Significant Unobservable Inputs (Level 3) | U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0
Significant Unobservable Inputs (Level 3) | Corporate Debt Securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	$ 0	$ 0

Available-for-Sale Investment_2

Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 76,323	$ 120,236
Gross unrealized gains		8
Gross unrealized losses	(433)	(53)
Fair Value	75,890	120,191
Commercial Paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	56,852	106,298
Gross unrealized gains		8
Gross unrealized losses	(238)	(29)
Fair Value	56,614	106,277
Corporate Debt Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		5,876
Gross unrealized losses		(3)
Fair Value		5,873
U.S. Government Agency Securities and Treasuries
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	19,471	8,062
Gross unrealized losses	(195)	(21)
Fair Value	$ 19,276	$ 8,041

Available-for-Sale Investment_3

Available-for-Sale Investments - Additional Information (Detail) $ in Millions	Jun. 30, 2022 USD ($) Security Investment	Dec. 31, 2021 USD ($) Investment
Investments, Debt and Equity Securities [Abstract]
Number of investments in unrealized loss position	27	20
Number of investments in unrealized loss position, more than twelve months	0	0
Aggregate fair value of securities in unrealized loss position | $	$ 75.9	$ 72.2
Number of securities with other than temporary impairment | Security	0

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 20,348	$ 19,714
Less accumulated depreciation	(11,884)	(10,626)
Property and equipment, net	8,464	9,088
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,196	8,274
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	795	756
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	500	500
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,820	9,561
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 37	$ 623

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll related	$ 2,203	$ 3,495
Professional fees	632	298
Research and development	216	336
Other	198	273
Total accrued expenses	$ 3,249	$ 4,402

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 31, 2021	Jun. 30, 2019	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Class Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs							$ 32,578
Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares		6,340,771	11,500,000				11,500,000
Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		2,548,117
Warrants exercise price per share		$ 9
Warrants exercise price per share paid at closing of offering		8.99
Ginkgo Bioworks, Inc.
Class Of Stock [Line Items]
Sale of stock, price per share		$ 9
Proceeds from issuance of common stock and pre-funded warrants		$ 79,900
Ginkgo Bioworks, Inc. | Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares		6,340,771
Ginkgo Bioworks, Inc. | Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		2,548,117
Warrants exercise price per share		$ 9
Warrants exercise price per share paid at closing of offering		$ 8.99
Warrants exercised					0
Cowen and Company, LLC | ATM
Class Of Stock [Line Items]
Sale of common stock, shares				2,447,211		0
Proceeds from issuance of common stock, net of issuance costs				$ 8,100
Jefferies, LLC | ATM
Class Of Stock [Line Items]
Sale of common stock, shares					0
Proceeds from issuance of common stock, net of issuance costs	$ 50,000

Stockholders Equity - Schedule

Stockholders Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2022 shares
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	5,276,726
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	20,705
Options Exercisable to Purchase Common Stock
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	2,707,904
Common Stock Issuable Under Pre-Funded Warrants
Class Of Stock [Line Items]
Total Shares of Common Stock Reserved for Future Issuance	2,548,117

Equity-based Compensation - Add

Equity-based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted		2,889,149
Weighted average exercise price		$ 1.84
Employee unrecognized compensation expense		$ 6.6
Employee unrecognized compensation cost, period of recognition		2 years 9 months 18 days
Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee unrecognized compensation expense		$ 1.4
Employee unrecognized compensation cost, period of recognition		3 years 3 months 18 days
Number of restricted stock awards granted		507,260
Weighted average grant date fair value		$ 1.97
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares available for issuance (in shares)	696,988
Shares available for future grants		1,341,339
Plan 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares available for issuance (in shares)	3,484,942
2017 Plan and 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		2,259,432

Equity-based Compensation - Sch

Equity-based Compensation - Schedule of Equity-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 977	$ 876	$ 1,867	$ 1,753
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	378	359	753	774
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 599	$ 517	$ 1,114	$ 979

Equity-based Compensation - S_2

Equity-based Compensation - Schedule of Equity-based Compensation Expenses by Award Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 977	$ 876	$ 1,867	$ 1,753
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	845	800	1,665	1,499
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	113	62	166	234
ESPP
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 19	$ 14	$ 36	$ 20

Collaboration Agreements - Addi

Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of revenue		$ 152	$ 246	$ 396	$ 246
Current deferred revenue		149		149		$ 531
Ginkgo Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Prepayment to related party for collaboration agreement	$ 30,000			30,000
Related party transaction collaboration agreement, initial term	5 years
Current pre-paid research and development		1,700		1,700
Non-current pre-paid research and development		7,800		7,800
Roche Collaboration and Option Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of revenue				400
Roche Collaboration and Option Agreement | Current Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Current deferred revenue		$ 100		$ 100

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail) - $ / shares	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2021	Jun. 30, 2021
Common Stock $0.001 Par Value
Number of shares sold	6,340,771	11,500,000	11,500,000
Pre-Funded Warrants
Warrants to purchase shares of common stock	2,548,117
Warrants exercise price per share	$ 9
Warrants exercise price per share paid at closing of offering	$ 8.99

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Unvested Restricted Common Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	670,950	346,461
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	6,923,868	4,605,714
Potential Shares Issuable Under ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	20,705	10,240

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jan. 21, 2022	Dec. 31, 2021
Gain Contingencies [Line Items]
Estimated project cost for access personal support and other services	$ 1,800,000
Right of use asset - operating lease	15,034,000		$ 13,889,000
Azzur
Gain Contingencies [Line Items]
Agreed to pay to renovate and upgrade cleanroom space		$ 650,000
Right of use asset - operating lease	$ 2,900,000

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Common stock, outstanding		70,230,235	70,230,235	69,698,844
Ginkgo Bioworks, Inc.
Related Party Transaction [Line Items]
Common stock, outstanding		6,340,771	6,340,771
Prepayment to related party for collaboration agreement	$ 30		$ 30
Related party transaction collaboration agreement, initial term	5 years
Current Pre-Paid Research and Development		$ 1.7	1.7
Non Current Pre-Paid Research and Development		7.8	7.8
Prepaid research and development expenses		$ 1.2	$ 1.7